Page 92 - Contract Development News Today

/PRNewswire/ -- The "US Healthcare CDMO Market 2020-2026" report has been added to ResearchAndMarkets.coms offering. The US healthcare CDMO market is...

The "North American Healthcare CDMO Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.

Dublin, June 10, 2021 (GLOBE NEWSWIRE) -- The "US Healthcare CDMO Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The US healthcare CDMO market is estimated to grow significantly during the forecast period. The major factors that are projected to contribute to the growth of the market include the presence of contract manufacturers in the US that has significantly minimized costs and reduce product development time. Moreover, the growing demand for gen...

Regulatory News: Eurofins Scientific (Paris:ERF): 4 June 2021 April 2021 has delivered another strong trading performance, continuing the positive trends seen in Q1 and reflecting both the

VIVEbiotech launches lentiviral vector manufacturing plant for cell and gene therapy sectorSan Sebastián, Spain, June 4, 2021 - VIVEbiotech, S.L.,  a gene transfer technologies Contract Development and Manufacturing Organization (CDMO) developing and GMP manufacturing lentiviral vectors, today...

Regulatory News: Eurofins Technologies (Paris:ERF) announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 Variants of Concern including

About Eurofins Technologies - a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries. About Eurofins - the global ...

Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing end-to-end contract development and manufacturing services, today announced its plans to add mRNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022. mRNA has been the technology of choice for many COVID-19 vaccines due to its characteristics of safety, and fast scalability in manufacturing.

Investegate announcements from Odyssean Inv. Trust, Annual Financial Report

05/28/21 Pharmaceutical Online Newsletter